Brief: Iterum Announces Beginning Of Dosing In Phase 3 Trial Of Oral Sulopenem In Uncomplicated Urinary Tract Infections
20/10/2022 13:03
Oct 20 (Reuters) - Iterum Therapeutics PLC ITRM.O :
* ITERUM ANNOUNCES FIRST PATIENT DOSED IN REASSURE, A PHASE
3
CLINICAL TRIAL OF ORAL SULOPENEM IN UNCOMPLICATED URINARY TRACT
INFECTIONS
* ITERUM THERAPEUTICS PLC - NDA RESUBMISSION EXPECTED IN
SECOND
HALF OF 2024
Source text for Eikon: ID:nGNX1H9RRg
Further company coverage: ITRM.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Iterum Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Entergy, US natgas stocks, Brown-Forman, Datacentrex
U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services
Iterum Therapeutics plummets after filing wind up petition
Iterum seeks court-led dissolution amid cash crisis, inability to raise funds (updated)
Iterum files wind-up petition due to limited cash, inability to raise equity